News
21h
Zacks Investment Research on MSNCan Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...
In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...
The foundation behind Novo Nordisk A/S (NVO) and the Danish government will invest €80 million ($93 million) in a Microsoft ...
Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...
Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...
Explore more
3d
Zacks.com on MSNNovo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.
Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing WeightWatchers to reboot its drug strategy.
Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results